The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ...
PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan PeptiDream Inc., a public Kanagawa, Japan-based ...
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). 177 Lu-PSMA-I&T is a radiotherapeutic agent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results